Beta Bionics, Inc. (BBNX) Builds Diabetes TechnologyBeta Bionics, Inc.NASDAQ:BBNXtraderspro_chartsBeta Bionics, Inc. (BBNX) develops diabetes technology designed to make insulin therapy simpler and more automated. Its iLet Bionic Pancreas uses continuous glucose data to calculate and deliver insulin with less input from the user. Growth comes from wider adoption of automated insulin delivery, expanded access to iLet, new pump technology, and growing demand for easier diabetes management. On the chart, BBNX printed a confirmation bar with increasing volume as price moved above the .236 Fibonacci level and into the momentum zone. A trailing stop can be established using Fibonacci levels on the Fibonacci snap tool, helping manage risk while allowing momentum to continue.